Preferred Label : Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039A;
NCIt synonyms : Anti-PD-1/VEGF Bispecific Antibody MHB039A; PD-1 x VEGF Bispecific Antibody MHB039A; Anti-VEGF/Anti-PD-1 Bispecific Antibody MHB039A;
NCIt definition : A bispecific antibody directed against the negative immunoregulatory human cell receptor
programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial
growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic
and antineoplastic activities. Upon administration, anti-PD-1/anti-VEGF bispecific
antibody MHB039A simultaneously targets and binds to both PD-1 expressed on T-cells
and VEGF expressed on tumor cells. The binding of MHB039A to PD-1 prevents the activation
of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1; CD274) and/or 2 (PD-L2;
CD273). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes
and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead
to a reduction in tumor growth. The binding of MHB039A to VEGF prevents binding of
VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to
the inhibition of vascular endothelial cell proliferation. The inhibition of tumor
angiogenesis may further decrease tumor cell proliferation and prevent metastasis.
PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on
T-cells, functions as an immune checkpoint that negatively regulates T-cell activation
and effector function when activated by its ligands PD-L1 and/or PD-L2; it plays an
important role in tumor evasion from host immunity. VEGF is overexpressed in a variety
of cancers and is associated with increased invasiveness and decreased survival.;
Molecule name : MHB-039A; MHB 039A;
Origin ID : C212934;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
